Table 3.
Concordance between assigned Kidney Function Categories using the Cockcroft-Gault Equation versus CKD-EPI and MDRD Study equations in Selected Subgroups
| Concordant (%) Kappa (95% CI) |
||
|---|---|---|
|
|
||
| CKD-EPI | MDRD Study | |
| Overalla | 85 0.77 (0.69, 0.85) |
79 0.69 (0.60, 0.77) |
| Tenofovir Use/Exposure | ||
| Yes | 87 0.79 (0.70, 0.89) |
79 0.68 (0.57, 0.79) |
| No | 81 0.73 (0.59, 0.87) |
79 0.70 (0.56, 0.84) |
| Age group, years | ||
| ≤50 | 91 0.83 (0.73, 0.92) |
85 0.74 (0.63, 0.84) |
| >50 | 74 0.64 (0.48, 0.79) |
68 0.57 (0.40, 0.73) |
| Sex | ||
| Women | 84 0.77 (0.63, 0.91) |
76 0.67 (0.52, 0.83) |
| Men | 86 0.76 (0.66, 0.86) |
80 0.69 (0.58, 0.79) |
| Race | ||
| African Americans | 82 0.73 (0.63, 0.84) |
79 0.69 (0.58, 0.81) |
| White or other | 89 0.81 (0.69, 0.92) |
79 0.69 (0.56, 0.81) |
| BMI group, kg/m2 | ||
| <22 | 66 0.60 (0.41, 0.79) |
77 0.72 (0.54, 0.89) |
| 22-30 | 92 0.86 (0.78, 0.94) |
83 0.74 (0.64, 0.84) |
| >30 | 81 0.61 (0.40, 0.82) |
67 0.41 (0.21, 0.62) |
| HIV RNA viral load, copies/mL | ||
| Undetected | 81 0.74 (0.63, 0.85) |
73 0.64 (0.53, 0.76) |
| <1000 | 95 0.88 (0.75, 1.00) |
90 0.77 (0.60, 0.95) |
| ≥1000 | 86 0.77 (0.48, 1.00) |
86 0.77 (0.48, 1.00) |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology collaboration; MDRD Study, Modification of Diet in Renal Disease Study; BMI, body mass index
a
Concordance rates were statistically different, p< 0.001
Tenofovir (Viread®)
Kidney Function categories from Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville: U.S. Department of Health and Human Services; May 1998 [22]